

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of

(a) silibin silibinin or a salt thereof

and

(b) α -lipoic acid or a salt thereof,

and a pharmaceutical carrier for each (a) and (b),

wherein each of (a) and (b) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

Claim 2. (Previously Presented) The method according to claim 1, wherein said subject is a human patient and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d.

Claim 3. (Currently Amended) The method according to Claim 1, wherein said subject is a human patient and the dose of said silibin silibinin or a salt thereof is between 20 and 1600 mg/d.

Claim 4. (Cancelled)

Claim 5. (Currently Amended) ~~The method according to Claim 1, comprising administering to said subject~~ A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of

(a) silibinin or a salt thereof,

(b) α -lipoic acid or a salt thereof, and

(c) an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent,

wherein each of (a), (b) and (c) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

Claim 6. (Previously Presented) The method according to Claim 1, wherein each of (a) and (b) is presented in the form of an aerosol.

Claim 7. (Currently Amended) The method according to Claim 1, wherein silibinin silibinin or a salt thereof and the α -lipoic acid or a salt thereof is presented in a single formulation.

Claim 8. (Currently Amended) The method according to Claim 1, wherein silibinin silibinin or a salt thereof and the α -lipoic acid or a salt thereof are presented in separate formulations.

Claim 9. (Cancelled)

Claim 10. (Currently Amended) The method according to Claim 1, wherein an effector of glutathione metabolism the silibinin or a salt thereof and the α -lipoic acid or a salt thereof are presented in a single formulation.

Claim 11. (Currently Amended) The method according to Claim 1, wherein an effector of glutathione metabolism the silibinin or a salt thereof and the α -lipoic acid or a salt thereof are presented in separate formulations.

Claim 12. (Currently Amended) A The method according to Claim 1, wherein the combination consists of

(a) silibinin and

(b) α -lipoic acid, for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases comprising administering silibinin, its salts and/or its pro-drugs with α -lipoic acid

Claim 13. (Previously Presented) The method according to claim 2, wherein the dose of α -lipoic acid or a salt thereof is between 200 and 600 mg/d.

Claim 14. (Currently Amended) The method according to claim 3, wherein the dose of silibinin silibinin or a salt thereof is between 300 and 800 mg/d.

Claim 15. (Currently Amended) The method according to Claim 1, wherein said subject is a human patient and the dose of said ~~sibillin~~ silibinin or a salt thereof is between 20 and 1600 mg/d and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d.